QALSODY Patent Gets FDA Boost: Generic Snooze Fest
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for QALSODY, a human drug product, so its patent can be extended. This helps the company behind QALSODY get extra time to protect their invention before generics can enter the market. If you’re in the drug business or follow patents, this means a bit more time before cheaper versions show up, potentially affecting prices and competition.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA OKs Patent Extension for QALSODY
The FDA has set the regulatory review period for the drug QALSODY so its patent can be extended. That gives the company more time before cheaper generic versions can enter the market, which could affect prices and competition for this drug.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in